No therapies are FDA approved for NASH, but I believe metabolic, inflammatory, and fibrotic aspects of NASH will all shape its management.
Why the path to HCV elimination must reach PWID.
We must stay the course to eliminate HBV as a public health threat.
How long should patients with chronic hepatitis B be treated with nucleos(t)ide analogues? When should we treat patients with immune-tolerant hepatitis B? Here’s my take.
How can providers ensure that vulnerable populations are linked to HCV testing and care? Here’s my take on what we should be doing in our practice.
Here’s my take on bariatric surgery, noninvasive testing, and endpoints in patients with NASH.
Download HBV slide highlights from our live symposium.
Download HCV slide highlights from our live symposium.
Download NASH slide highlights from our live symposium.
In this video from a live symposium, expert faculty discuss approaches to improve diagnosis and treatment of hepatitis C, hepatitis B, and NASH with an emphasis on how clinicians can maximize liver health.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.